ストックスクリーナーアプリを入手
0.587
2.51%
-0.0151
プレマーケット:
.56
-0.027
-4.60%
Neurosense Therapeutics Ltd (NRSN) 最新ニュース
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Revision Upgrade - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NRSN Forecast — Price Target — Prediction for 2027 - TradingView
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD - GuruFocus
Price to book forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s - Stock Titan
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PR Newswire
Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to EBIT forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EverythingALS to Host NeuroSense in a Community Event Named: PrimeCConnecting the Dots - The AI Journal
EverythingALS to Host NeuroSense in a Community Event Named: Pri - GuruFocus
ALS community event puts NeuroSense’s PrimeC data in focus June 24 - Stock Titan
NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NeuroSense (NRSN) CFO acquires 250,000 shares in private placement - Stock Titan
Neurosense Therapeutics Ltd (NRSN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd (NRSN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSN) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRSN Q1'26 Earnings: revenue estimate is 514.10K USD - TradingView
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):